Scientists try drug duo to Re-Sensitize stubborn thyroid tumors
NCT ID NCT04462471
Summary
This early-stage study tested a combination of two drugs, vemurafenib and copanlisib, in patients with a specific type of advanced thyroid cancer that had stopped responding to standard radioactive iodine therapy. The main goals were to find the safest dose of the drug combination and to see if this pre-treatment could make the tumors sensitive to radioactive iodine again, potentially allowing patients to benefit from this standard treatment. The study involved 8 adults with BRAF-mutant thyroid cancer that was resistant to radioactive iodine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
-
Memorial Sloan-Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.